The FDA approves Allergan's (NYSE:AGN) JUVEDERM VOLLURE XC for the correction of moderate-to-severe facial wrinkles and folds, such as nasolabial (smile lines) folds, in adults at least 21 years old. It will be commercially available starting next month.
The company says JUVEDERM VOLLURE XC is formulated with its proprietary VYCROSS technology that gives the gel extended duration (up to 18 months) by virtue of blending different molecular weights of hyaluronic acid (HA). It was approved in Europe in 2013 under the brand name JUVEDERM VOLIFT.
Subscribe for full text news in your inbox